Acute Leukemias - Republican Scientific Medical Library

72 Chapter 4 · Relapsed and Refractory Acute Myeloid Leukemia
older patients: The results of the United Kingdom Medical Research
Council AML11 trial. Blood 98(5):1302–1311
7. Lee S, Tallman MS, Oken MM, et al. (2000) Duration of second
complete remission compared with first complete remission in
patients with acute myeloid leukemia. Eastern Cooperative Oncology
Group. Leukemia 14(8):1345–1348
8. Estey EH (2000) Treatment of relapsed and refractory acute myelogenous
leukemia. Leukemia 14(3):476–479
9. Keating MJ, Kantarjian H, Smith TL, et al. (1989) Response to salvage
therapy and survival after relapse in acute myelogenous leukemia.
J Clin Oncol 7(8):1071–1080
10. Breems DA, Van Putten WL, Huijgens PC, et al. (2005) Prognostic
index for adult patients with acute myeloid leukemia in first relapse.
J Clin Oncol 23(9):1969–1978
11. Giles F, Verstovsek S, Garcia-Manero G, et al. (2006) Validation of
the European Prognostic Index for younger adult patients with
acute myeloid leukaemia in first relapse. Br J Haematol
134(1):58–60
12. Lo Coco F, Diverio D, Avvisati G, et al. (1999) Therapy of molecular
relapse in acute promyelocytic leukemia. Blood 94(7):2225–2229
13. Marcucci G, Mrozek K, Ruppert AS, et al. (2004) Abnormal cytogenetics
at date of morphologic complete remission predicts short
overall and disease-free survival, and higher relapse rate in adult
acute myeloid leukemia: Results from cancer and leukemia group
B study 8461. J Clin Oncol 22(12):2410–2418
14. Sternberg DW, Aird W, Neuberg D, et al. (2000) Treatment of patients
with recurrent and primary refractory acute myelogenous
leukemia using mitoxantrone and intermediate-dose cytarabine:
A pharmacologically based regimen. Cancer 88(9):2037–2041
15. Kern W, Aul C, Maschmeyer G, et al. (1998) Superiority of highdose
over intermediate-dose cytosine arabinoside in the treatment
of patients with high-risk acute myeloid leukemia: Results
of an age-adjusted prospective randomized comparison. Leukemia
12(7):1049–1055
16. Rees JK, Gray RG, Swirsky D, et al. (1986) Principal results of the
Medical Research Council’s 8th acute myeloid leukaemia trial. Lancet
2(8518):1236–1241
17. Appelbaum FR, Rowe JM, Radich J, et al. (2001) Acute myeloid leukemia
hematology. Am Soc Hematol Educ Program, pp 62–86
18. Burnett AK, Mohite U (2006) Treatment of older patients with
acute myeloid leukemia7New agents. Semin Hematol 43(2):
96–106
19. Estey E, Plunkett W, Gandhi V, et al. (1993) Fludarabine and arabinosylcytosine
therapy of refractory and relapsed acute myelogenous
leukemia. Leuk Lymphoma 9(4–5):343–350
20. Thalhammer F, Geissler K, Jager U, et al. (1996) Duration of second
complete remission in patients with acute myeloid leukemia treated
with chemotherapy: A retrospective single-center study. Ann
Hematol 72(4):216–222
21. Estey E (1996) Treatment of refractory AML. Leukemia 10(6):932–
936
22. Appelbaum FR, Gundacker H, Head DR, et al. (2006) Age and acute
myeloid leukemia. Blood 107(9):3481–3485
23. Kantarjian HM, Keating MJ, Walters RS, et al. (1988) The characteristics
and outcome of patients with late relapse acute myelogenous
leukemia. J Clin Oncol 6(2):232–238
24. Wheatley K, Burnett AK, Goldstone AH, et al. (1999) A simple, robust,
validated and highly predictive index for the determination
of risk-directed therapy in acute myeloid leukaemia derived from
the MRC AML 10 trial. United Kingdom Medical Research Council’s
Adult and Childhood Leukaemia Working Parties. Br J Haematol
107(1):69–79
25. Kern W, Haferlach T, Schoch C, et al. (2003) Early blast clearance by
remission induction therapy is a major independent prognostic
factor for both achievement of complete remission and long-term
outcome in acute myeloid leukemia: Data from the German AML
Cooperative Group (AMLCG) 1992 Trial. Blood 101(1):64–70
26. Weltermann A, Fonatsch C, Haas OA, et al. (2004) Impact of cytogenetics
on the prognosis of adults with de novo AML in first relapse.
Leukemia 18(2):293–302
27. Kern W, Haferlach T, Schnittger S, et al. (2002) Karyotype instability
between diagnosis and relapse in 117 patients with acute myeloid
leukemia: Implications for resistance against therapy. Leukemia
16(10):2084–2091
28. Estey E, Keating MJ, Pierce S, et al. (1995) Change in karyotype
between diagnosis and first relapse in acute myelogenous leukemia.
Leukemia 9(6):972–976
29. Anderlini P, Luna M, Kantarjian HM, et al. (1996) Causes of initial
remission induction failure in patients with acute myeloid leukemia
and myelodysplastic syndromes. Leukemia 10(4):600–608
30. Glasmacher A, Prentice A, Gorschluter M, et al. (2003) Itraconazole
prevents invasive fungal infections in neutropenic patients treated
for hematologic malignancies: Evidence from a meta-analysis
of 3597 patients. J Clin Oncol 21(24):4615–4626
31. Mengis C, Aebi S, Tobler A, et al. (2003) Assessment of differences
in patient populations selected for excluded from participation in
clinical phase III acute myelogenous leukemia trials. J Clin Oncol
21(21):3933–3939
32. van Prooijen HC, Dekker AW, Punt K (1984) The use of intermediate
dose cytosine arabinoside (ID Ara-C) in the treatment of acute
non-lymphocytic leukaemia in relapse. Br J Haematol 57(2):291–
299
33. Herzig RH, Lazarus HM, Wolff SN, et al. (1985) High-dose cytosine
arabinoside therapy with and without anthracycline antibiotics
for remission reinduction of acute nonlymphoblastic leukemia.
J Clin Oncol 3(7):992–997
34. Capizzi RL, Powell BL (1987) Sequential high-dose ara-C and asparaginase
versus high-dose ara-C alone in the treatment of patients
with relapsed and refractory acute leukemias. Semin Oncol 14(2
Suppl 1):40–50
35. Capizzi RL, Davis R, Powell B, et al. (1988) Synergy between highdose
cytarabine and asparaginase in the treatment of adults with
refractory and relapsed acute myelogenous leukemia7A Cancer
and Leukemia Group B Study. J Clin Oncol 6(3):499–508
36. Carella AM, Carlier P, Pungolino E, et al. (1993) Idarubicin in combination
with intermediate-dose cytarabine and VP-16 in the
treatment of refractory or rapidly relapsed patients with acute
myeloid leukemia. The GIMEMA Cooperative Group. Leukemia
7(2):196–199
37. Karanes C, Kopecky KJ, Head DR, et al. (1999) A phase III comparison
of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone
in the treatment of first relapsed or refractory acute myeloid leukemia
Southwest Oncology Group Study. Leuk Res 23(9):787–794
38. Tavernier E, Le QH, Elhamri M, et al. (2003) Salvage therapy in refractory
acute myeloid leukemia: Prediction of outcome based on
analysis of prognostic factors. Leuk Res 27(3):205–214